Utilising our expertise in complex market access and regulatory consulting, Commercial Eyes (CE) was engaged to develop:
- Comprehensive market assessment: Evaluate financial and market opportunities within key application areas, focusing on blood
- Regulatory and competitive analysis: landscape and competitive positioning in the US, EU, and Australian markets to inform a go-to-market strategy.
- Development of go-to-market documentation: Create a business case and go-to-market strategy to support Vitrafy’s commercialisation and capital-raising efforts.
As part of this assessment, we implemented a structured, multi-phase approach:
- Conducted secondary research to identify market trends, key drivers, and competitive positioning.
- Compiled findings into a detailed report outlining opportunities and threats.
- Conducted in-depth assessments of market potential in the US and Australia for blood platelets, cell and gene therapies, and animal breeding programs.
- Identified key market participants, demand drivers, and regulatory requirements for each segment.
- Developed comprehensive go-to-market materials, including:
- Situation analysis, value proposition, and competitor analysis.
- Target audience segmentation, product positioning, and distribution strategies.
- Presented a business case and strategic roadmap to support Vitrafy’s capital-raising efforts.
OUTCOME
CE’s strategic research and analysis delivered several critical outcomes:
- Global market potential: Identified significant growth opportunities across multiple sectors, with the cryopreservation market projected to grow substantially by 2030.
- Regional focus: Recommended a phased approach targeting key markets in the US and Australia, supported by regulatory insights to streamline the process.
- Regulatory pathways: Mapped regulatory requirements for each target market, providing a clear pathway for compliance and approval.
- Competitive edge: Positioned Vitrafy’s technology as a superior solution, highlighting its ability to reduce cellular damage and enhanced post-thaw viability.
- Targeted segments: Prioritised high-growth areas such as blood platelets, cell and gene therapy and animal breeding to maximise market impact.
- Integrated solutions: Emphasised Vitrafy’s proprietary hardware and software capabilities, including their digital platform, for end-to-end supply chain management and data integration.
CONCLUSION
Commercial Eyes’ comprehensive assessment of and insights into the cryopreservation market, regulatory landscape, and competitive dynamics supported Vitrafy to develop their capital raise documents and their company prospectus.
Congratulations to Vitrafy on their recent successful IPO! We are pleased to have supported Vitrafy on this journey as it enters key markets and advances its mission to revolutionise cryopreservation technologies.
At Commercial Eyes, we understand the complexities of diverse healthcare markets. Our research expertise equips you with the insights needed to uncover opportunities and prioritise them effectively.
We specialise in supporting your capital raise efforts by delivering high-quality, investor-ready documentation tailored to your needs.
Reach out to us today to discover how we can help drive your innovation forward.
Jo Atkins
Head of Access Research and Intelligence
Jo is a registered pharmacist with post graduate qualifications in Health Economics and a Master of Management with a major in Marketing from the Macquarie Graduate School of Management...
View Profile